During the past few decades, a number of circulating markers have been proposed for the early detection of ovarian cancer, and two of the commonly used biomarkers (carbohydrate antigen 125 [CA125] and human epididymis protein 4 [HE4]) have been approved by the US FDA for the risk assessment or management of ovarian cancer [42]. This evidence concerns the gene WFDC2 and ovarian carcinoma.